Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

World’s leading provider of heart valves and hemodynamic monitoring Edwards Lifesciences Corporation (EW - Analyst Report) disclosed positive one-year data on Edwards Sapien XT transcatheter aortic heart valve from the post-approval study in Europe. The company presented the data from the SOURCE XT Registry at the EuroPCR 2013 in Paris.

The SOURCE XT Registry is evaluating the performance of Edwards Sapien XT on high-risk and inoperable patients with acute, symptomatic aortic stenosis in an actual commercial setting. The patients were enrolled between Jul 2012 and Oct 2012 and will be monitored closely over five years.

The one-year outcome from this monitored and adjudicated prospective registry from 17 nations across Europe depicts the clinical efficacy of the company’s Sapien XT with improved patient outcomes.  According to the data from EuroPCR, Edwards Sapien XT has immense potential as it eliminates procedural complications and leads to fewer vascular events in patients.

The affirmative data from consecutively enrolled 2,688 inoperable patients at 93 centers assesses the performance of the transcatheter aortic valve replacement (TAVR). This reflects over 20% of the total number of patients treated with Edwards Sapien XT during the time period of the post-approval study.  

The data from Europe demonstrates the clinical benefits of the company’s lower-profile Sapien XT valve. The positive patient outcomes on Sapien XT from actual and clinical trial settings are encouraging.

Other Updates on Sapien XT

While data from Europe continues to demonstrate the clinical competency of the Sapien XT valve, the valve is yet to be launched in the U.S. Edwards continues to enroll patients in the intermediate risk cohort (Cohort A) of The Partner II Trial in the U.S. The enrollment is expected to round off by mid-2013.

With plans to submit Cohort B clinical results from The Partner II Trial for the U.S. Food and Drug Administration (FDA) approval shortly, Edwards envisages the U.S. approval to come through in 2014. The company also expects regulatory approval and reimbursement in Japan for Sapien XT in the ongoing year.

Our Take

We believe that the transcatheter aortic valves offer the most promising opportunity in the cardiac device space for Edwards. Despite a sluggish first quarter, the company believes the transcatheter heart valve (THV) product group remains the revenue driver and is expected to do well in the upcoming quarters. We also believe that the THV segment of the company has the potential to lead sales and earnings over the long haul.

With a dismal start to 2013 when Edwards’ revenues and earnings missed the Zacks Consensus Estimate and considerable guidance cut, the estimate revision trend also reflects a bearish tone towards the stock. As a result, the stock carries a Zacks Rank #4 (Sell). While we prefer to avoid Edwards, we believe that other medical stock such as Conceptus Inc. , CONMED Corporation (CNMD - Analyst Report) and The Copper Companies (COO - Analyst Report) are worth considering. These stocks carry a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
LAKE SHORE G LSG 0.77 +6.05%
SKECHERS USA SKX 38.53 +4.50%
QUESTCOR PHA QCOR 80.07 +2.47%
VIPSHOP HOLD VIPS 156.35 +1.82%
ENLINK MIDS ENLC 36.29 +1.60%